Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study - Top-Institutions - MDSpire

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • By

  • Simran Chandra

  • Sagar Hansraj

  • Aakriti Adhikari

  • Ben Ponvilawan

  • Addison Tolentino

  • Dhruv Bansal

  • April 27, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hematology
    • Immunotherapy Toxicity Management

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Hematology
    • Thoracic Oncology
    • Immunology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Hematology
    • Translational Research

  • #4

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Research
    • Immunology
    • Hematology
    • Clinical Trials

Original Source(s)

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • by Simran Chandra, Sagar Hansraj, Aakriti Adhikari, Ben Ponvilawan, Addison Tolentino, Dhruv Bansal

  • April 27, 2026

Related Content

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship